Figure 3

ROCK1 in human brain tissue.

(A) Western blot of ROCK1 protein levels in the different tissue fractions (TBS = soluble fraction, SDS = SDS fraction, see methods) of the inferior temporal lobe of donors at different stages of AD pathology. (B) Relative quantitation of the ROCK1 Western blots in the different tissue fractions shown in (A). (C) Quantitation of the numbers of phospho-tau-immunoreactive tangles (open bars) and those colocalising ROCK1 (shaded bar) at different stages of AD. Significant increases in both types of tangles occur with increasing stages of AD. (D) Representative examples of double-labelled phospho-tau- (p-Tau) and ROCK1-immunoreactive tangles at the different stages of AD indicated at left. Brain tissue samples from healthy aged controls (N = 5 aged 89 ± 4 y, Braak neuritic stages 0–2), preclinical AD (N = 4 aged 85 ± 3 y, Braak neuritic stages 3–4) and clinical end-stage AD (N = 8 aged 86 ± 4 y, Braak neuritic stages 5–6). All data are expressed as mean ± SD with at least three replications of the Western blot data. Scale in (D) is equivalent for all micrographs.